BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is a Healthcare company (Biotechnology) with a market capitalization of $156M. The Maz Rating grades it against the other companies in its sector.
BridgeBio Oncology Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.94, BridgeBio Oncology Therapeutics Inc. trades at 0.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -49.0%, return on invested capital of -63.3% and a free cash flow yield of -96.3%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.08. Over the past 52 weeks the share price ranged from $1.93 to $14.87, with a beta of 0.39.
BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 82.8% / 30% · Interest income / Revenue 326200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 50.9% / 33% · Receivables / Mkt Cap (36m) 0.04% / 49% · Interest income / Revenue 326200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 50.9% / 33.33% · Receivables / Mkt Cap (24m) 0.04% / 33.33% · Interest income / Revenue 326200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.37% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.1% / 33.33% · Receivables / Avg Assets (4Q) 0.04% / 33.33% · Interest income / Revenue 326200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 56.0% / 33.33% · (Cash+Recv) / Total Assets 56.0% / 33.33% · Interest income / Revenue 326200000.0% / 5% | Fail |
No. As of September 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. BridgeBio Oncology Therapeutics Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 326200000.0% of each dividend: BridgeBio Oncology Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.